Prior therapy defines mutation profiles in childhood cancer at relapse

A groundbreaking study has revealed how prior cancer treatments shape the genetic makeup of childhood cancers upon relapse, offering new insights into the long-term consequences of therapeutic interventions. The research, published in Nature News, analyzed the mutational profiles of tumors in children who had undergone intensive chemotherapy and radiation therapy, uncovering distinct genetic fingerprints linked to specific treatments. These findings suggest that the very therapies designed to eliminate cancer may inadvertently alter the tumor's DNA, influencing future responses to treatment and increasing the risk of secondary malignancies. The study examined 611 whole-genome-sequenced tumor samples from 544 pediatric patients enrolled in three international precision medicine programs: SickKids Cancer Sequencing (KiCS) in Canada, ZERO in Australia, and MSK in the United States. Each program focuses on treating children with aggressive forms of cancer, ensuring a diverse and representative sample. Detailed records of the patients' exposure to 86 different therapies were integrated with the genomic data, allowing researchers to trace the mutational changes induced by specific chemotherapeutic agents. The results showed that post-treatment tumors exhibited significantly higher mutation burdens compared to pre-treatment samples, indicating that previous therapies had left lasting marks on the genome. One of the key discoveries was the identification of unique mutational signatures, patterns of genetic alterations that reflect the influence of particular treatments. These signatures emerged after exposure to certain chemotherapies and were found to correlate with treatment resistance and poorer clinical outcomes. For example, platinum-based drugs, known for their effectiveness against some cancers, were linked to specific mutational patterns that persisted even after treatment. Similarly, temozolomide, a commonly used alkylating agent, was associated with previously suspected mutagenic effects. By mapping these signatures, researchers gained a clearer understanding of how different therapies contribute to the evolution of cancer over time. The study also highlighted the limitations of earlier research, which often relied on smaller sample sizes, limited sequencing techniques, or incomplete records of treatment regimens. As a result, previous analyses failed to capture the full extent of how therapy-induced mutations might affect tumor behavior. The current work addressed these gaps by using high-quality, whole-genome sequencing and meticulously curated data on drug exposure, enabling a more accurate assessment of the mutagenic impact of various treatments. Among the implications of the study is the potential to refine treatment strategies by identifying which therapies are more likely to induce harmful genetic changes. This knowledge could help clinicians make informed decisions about de-escalating treatment intensity while still achieving effective remission. Additionally, the findings underscore the importance of monitoring long-term health outcomes in childhood cancer survivors, particularly given the increased risk of developing secondary cancers and other late-effects of therapy. Researchers emphasize that further investigation is needed to determine whether these therapy-related mutations are specific to certain tissues or whether they affect multiple organ systems. Understanding this could lead to more personalized approaches to cancer care, tailored to minimize the risk of long-term complications. The study represents a critical step toward improving both the efficacy and safety of cancer treatments for children, ultimately aiming to enhance survivorship and quality of life.